Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Phase 1 Active not recruiting 9 enrolled Washington University School of Medicine Geneos Therapeutics · collab National Institute of Neurological Disorders and Stroke (NINDS) · collab The Foundation for Barnes-Jewish Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single institution, open-label, single arm, study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine in subjects with newly diagnosed, unmethylated glioblastoma.

Timeline

Start: 2020-07-14
Primary completion: 2022-05-13
Completion: 2027-09-03

Publications

Garfinkle EAR, Perales-Linares R, Gimple RC, Livingstone AJ, Roberts KF, Butt OH, Goedegebuure SP, McLellan MD, Chang GS, Hundal J, Yan J, Navarro JB, Paxton SA, Chattopadhyay S, Cooch N, Perales-Puchalt A, Stavroulaki K, Rochestie S, Peters J, Junker B, Campian JL, Chheda MG, Chicoine MR, Kim AH, Willie JT, Zipfel GJ, Dowling JL, Miller CA, Griffith OL, Griffith M, Gillanders WE, Miller KE, Mardis ER, Sardesai NY, Dunn GP, Johanns TM. Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial. Nat Cancer. 2026 May 12. doi: 10.1038/s43018-026-01163-w. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Personalized neoantigen DNA vaccine	Vaccine	—	—
Subject	Rocakinogene Sifuplasmid	Vaccine	—	—

Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Summary

Timeline

Publications

Drugs

Indications